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The Endocrinology of Aging
Steven W. J. Lamberts,* Annewieke W. van den Beld,
Aart-Jan van der Lely
Most aging individuals die from atherosclerosis, cancer, or dementia; but in the oldest
old, loss of muscle strength resulting in frailty is the limiting factor for an individual’s
chances of living an independent life until death. Three hormonal systems show de-
creasing circulating hormone concentrations during normal aging: (i) estrogen (in meno-
pause) and testosterone (in andropause), (ii) dehydroepiandrosterone and its sulphate (in
adrenopause), and (iii) the growth hormone/insulin-like growth factor I axis (in somato-
pause). Physical changes during aging have been considered physiologic, but there is
evidence that some of these changes are related to this decline in hormonal activity.
Hormone replacement strategies have been developed, but many of their aspects remain
controversial, and increasing blood hormone levels in aging individuals to those found
during mid-adult life has not been uniformly proven to be safe and of benefit.
The average length of human life is cur-
rently 75 to 78 years and may increase to 85
years during the coming two decades (1),
but is not clear whether these additional
years will be satisfying to live. Most data
indicate a modest gain in the number of
healthy years lived but a far greater increase
in years of compromised physical, mental,
and social function (2). The number of days
of restricted activity and the number of
admissions to hospitals and nursing homes
sharply increases after age 70 (3). One U.S.
health interview survey indicates that, at
present, more than 25 million aging people
suffer from physical impairment, whereas
the number of people requiring assistance
with activities of daily living increases from
14% at age 65 to 75 to 45% in those over 85
years old (4).
Aging and Physical Frailty
Throughout adult life, all physiological
functions gradually decline (5). There is a
diminished capacity for cellular protein syn-
thesis, a decline in immune function, an
increase in fat mass, a loss of muscle mass
and strength, and a decrease in bone min-
eral density (5). Most elderly individuals
will die from atherosclerosis, cancer, or de-
mentia; but in an increasing number of the
healthy oldest old, loss of muscle strength is
the limiting factor that determines their
chances of living an independent life until
death.
Age-related disability is characterized by
generalized weakness, impaired mobility
and balance, and poor endurance. In the
oldest old, this state is called physical frail-
ty, which is defined as “a state of reduced
physiological reserves associated with in-
creased susceptibility to disability” (6).
Clinical correlates of physical frailty in-
clude falls, fractures, impairment in activi-
ties of daily living, and loss of indepen-
dence; falls contribute to 40% of admissions
to nursing homes (7).
Loss of muscle strength is an important
factor in the process of frailty. Muscle
weakness can be caused by aging of muscle
fibers and their innervation, osteoarthri-
tis, and chronic debilitating diseases (8).
However, a sedentary lifestyle and de-
creased physical activity and disuse are
also important determinants of the decline
in muscle strength. In a study of 100 frail
nursing home residents (average age 87
years), lower-extremity muscle mass and
strength were closely related (9). Super-
vised resistance exercise training (for 45
min three times per week for 10 weeks)
doubled muscle strength and significantly
increased gait velocity and stair-climbing
power. This demonstrates that frailty in
the elderly is not an irreversible effect of
aging and disease but can be reduced and
perhaps even prevented (9). Also, among
nondisabled elderly people living in the
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community, objective measures of lower-
extremity function are highly predictive of
subsequent disability (10). In a study we
conducted, the leg extensor power of 400
elderly, independently living men varied
widely (Fig. 1). Prevention of frailty can
be achieved only by exercise. However,
exercise is difficult to implement in the
daily routine of the aging population, and
the number of dropouts from exercise pro-
grams is very high (11).
Part of the aging process affecting body
composition (loss of muscle size and
strength, loss of bone, and increase in fat
mass) might also be related to changes in
the endocrine system (5, 12). Here we
analyze recent knowledge about the effects
of long-term hormonal replacement ther-
apy on body composition as well as on
atherosclerosis, cancer formation, and
cognitive function.
Endocrinology of Aging
The two clinically most important chang-
es in endocrine activity during aging in-
volve the pancreas and the thyroid. Ap-
proximately 40% of individuals 65 to 74
years old and 50% of individuals older
than 80 years have impaired glucose tol-
erance or diabetes mellitus, and nearly
half of elderly diabetics are undiagnosed
(13, 14). These persons are at risk of de-
veloping secondary, mainly macrovascu-
lar, complications at an accelerated rate
(15). Pancreatic, insulin receptor, and
post-receptor changes associated with ag-
ing are critical components of the endo-
crinology of aging: Apart from decreased
(relative) insulin secretion by the b cells,
peripheral insulin resistance related to
poor diet, physical inactivity, increased
abdominal fat mass, and decreased lean
body mass contribute to the deterioration
of glucose metabolism (15, 16). Dietary
management, exercise, oral hypoglycemic
agents, and insulin are the four compo-
nents of treatment of these patients,
whose medical care is costly and intensive
(17).
Age-related thyroid dysfunction is also
common in the elderly (18). Lowered plasma
thyroxine (T4) and increased thyrotropin-
stimulating hormone (TSH) concentrations
occur in 5 to 10% of elderly women (18).
These abnormalities are mainly caused by
autoimmunity and are therefore an expres-
sion of age-associated disease rather than a
consequence of the aging process (19, 20).
Normal aging is accompanied by a slight
decrease in pituitary TSH release (18), but
especially by a decreased peripheral degrada-
tion of T4, which results in a gradual age-
dependent decline in serum triiodothyronine
(T3) concentration, without an important
change in T4 levels (21). This slight decrease
in plasma T3 concentration occurs largely
within the broad normal range of the
healthy elderly population and has not been
convincingly related to functional changes
during the aging process (18). At present,
the question of whether healthy aging peo-
ple might benefit from T3 replacement ther-
apy remains uninvestigated.
The changes in insulin sensitivity and
thyroid function that occur in the aging
population are frequently of clinical impor-
tance and are recognized and treated as
diseases. Three other hormonal systems
show decreasing circulating hormone con-
centrations during normal aging, and these
changes have been considered mainly phys-
iologic (Figs. 2 and 3). In recent years,
hormone replacement strategies have been
developed, but many of their aspects remain
controversial, and increasing hormone blood
levels to those found in 30- to 50-year-old
individuals has not yet been uniformly prov-
en to be safe and of benefit.
The most dramatic and rapidly occur-
ring change in women around the age of
50 is menopause (22). Cycling estradiol
(E2) production during the reproductive
years is replaced by very low, constant E2.
For many years, the prevailing view was
that menopause resulted from an exhaus-
tion of ovarian follicles. An alternative
perspective is that age-related changes in
the central nervous system and the hypo-
thalamo-pituitary unit initiate the meno-
pausal transition. The evidence that both
the ovary and the brain are key pacemak-
ers in menopause is compelling (23).
Changes in the activity of the hypo-
thalamo-pituitary-gonadal axis in males
are slower and more subtle. During aging,
a gradual decline in serum total and free
testosterone (T) levels occurs (24). This
“andropause” is characterized by a de-
crease in testicular Leydig cell numbers
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Fig. 1. Muscle strength, as measured by maxi-
mum leg extensor power, in 400 healthy, indepen-
dently living, elderly men (mean age, 78 years; age
range, 73 to 94 years). The maximum value of
three measurements of both legs is shown. A
Hoggan microFET hand-held dynamometer was
used for the measurements (64).
Pacemaker
of aging?
GH
IGF-I
LH/FSH
E2    /T DHEA
ACTH =
Cortisol =
During aging:
   Menopause: E2
   Andropause: T
   Adrenopause: DHEA
   Somatopause: GH/IGF-I
Fig. 2. During aging, a decline
in the activities of a number of
hormonal systems occurs.
(Left) A decrease in GH re-
lease by the pituitary gland
causes a decrease in the pro-
duction of IGF-I by the liver
and other organs (somato-
pause). (Middle) A decrease
in release of gonadotropin lu-
teinizing hormone (LH) and
follicle-stimulating hormone
(FSH), together with a de-
creased secretion at the go-
nadal level (from the ovaries,
decreased E2; from the testi-
cle, decreased T), cause
menopause and andropause,
respectively. (Right) The ad-
renocortical cells responsible
for the production of DHEA
decrease in activity (adreno-
pause) without clinically evi-
dent changes in corticotropin
(ACTH) and cortisol secretion.
A central pacemaker in the
hypothalamus or higher brain
areas (or both) is hypothe-
sized, which together with
changes in the peripheral organs (the ovaries, testicles, and adrenal cortex)
regulate the aging process of these endocrine axes.
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and in their secretory capacity, as well as
by an age-related decrease in episodic and
stimulated gonadotropin secretion (25).
The second hormonal system demon-
strating age-related changes is the cir-
culating levels of dehydroepiandrosterone
(DHEA) and its sulphate (DHEAS), which
gradually decline with age, resulting in “ad-
renopause” (26, 27). Adrenal secretion of
DHEA gradually decreases over time,
whereas adrenocorticotropin (ACTH) se-
cretion, which is physiologically linked to
plasma cortisol levels, remains largely un-
changed. The decline in DHEA(S) levels in
both sexes contrasts therefore with the
maintenance of plasma cortisol levels and
seems to be caused by a selective decrease in
the number of functional zona reticularis
cells in the adrenal cortex rather than reg-
ulated by a central (hypothalamic) pace-
maker of aging (27).
The third endocrine system that gradu-
ally declines in activity during aging is the
growth hormone (GH)/insulin-like growth
factor I (IGF-I) axis (Fig. 2) (5, 28). Mean
pulse amplitude, duration, and fraction of
GH secreted, but not pulse frequency, grad-
ually decrease during aging. In parallel,
there is a progressive fall in circulating
IGF-I levels in both sexes (28). There is no
evidence for a “peripheral” factor in this
process of “somatopause,” and its triggering
pacemaker seems mainly localized in the
hypothalamus, because pituitary soma-
totrops, even of the oldest old, can be
restored to their youthful secretory capac-
ity during treatment with GH-releasing
peptides.
We do not know whether the changes
in gonadal function (menopause and an-
dropause) are interrelated with the pro-
cesses of adrenopause and somatopause,
which occur in both sexes. In addition,
functional correlates (such as muscle size
and function, fat and bone mass, progres-
sion of atherosclerosis, and changes in
cognitive function) have not been related
to these changes in endocrine activity.
However, a number of effects of normal
aging closely resemble features of (isolated)
hormonal deficiency (such as hypogonadism
and GH deficiency), which in mid-adult
patients are successfully reversed by replace-
ment therapy with the appropriate hormone
(29). Although aging does not simply re-
sult from a variety of hormone deficiency
states, medical intervention in the pro-
cesses of meno-, andro-, adreno-, or so-
matopause might successfully prevent or
delay some aspects of the aging process.
Menopause and Andropause
In most women, this period of decline in
estrogens is accompanied by vasomotor reac-
tions, depressed mood, and changes in skin
and body composition (increase in body fat
and decrease in muscle mass). In the subse-
quent years, the loss of estrogens is followed
by a high incidence of cardiovascular disease,
loss of bone mass, and cognitive impairment
(Fig. 3) (30). The average age of menopause
(51.4 years) has not changed over time and
seems to be largely determined by genetic
factors. Because life expectancy is increasing,
the time a woman spends after menopause
constitutes more than one third of her life.
Long-term (5 to 10 years) hormone replace-
ment with estrogens in combination with
progestins starting at menopause has many
advantages (31). Apart from relieving hot
flashes and mood changes, reducing skin and
reproductive tract atrophy (such as dryness
of the vagina and urinary incontinence), and
preventing changes in body composition, es-
trogen/progestin replacement therapy delays
atherosclerosis, loss of bone mass, and loss of
cognitive function. Life expectancy seems
not to be influenced by estrogen/progestin
replacement, but atherosclerosis and bone
loss are considerably delayed (Table 1) (31).
An exciting observation is the apparent de-
lay in the onset of Alzheimer’s disease in
women treated with hormone replacement
(32). The mechanisms of these estrogen ef-
fects on the aging brain are speculative at
present (33).
There are, however, also important
negative effects of estrogen/progestin re-
placement therapy during menopause.
The most compelling problem is the in-
creased incidence of breast cancer (Table
1) (34). Little data are available on the
effects of a yearly mammogram on morbid-
ity and mortality of breast cancer patients
diagnosed during or after hormone re-
placement therapy. In addition, the in-
convenience of irregular menstruations
has an effect on long-term compliance
with this treatment. [“Nonbleeding” estro-
gen/progestins have recently been devel-
oped, however (35)]. At present, the de-
cision to start hormone replacement at
menopause should be based on the indi-
vidual’s risk factors, her attitude toward
hormonal treatment, and knowledge of its
risks and benefits. Knowledge and educa-
tion influence this decision; in a recent
Swedish study, only 24% of women aged
54 years but 72% of female general prac-
titioners and 88% of female gynecologists
were on estrogen/progestin replacement
therapy (36).
A new development in the search for
optimalizing hormone replacement therapy
during menopause came from observations
Fig. 3. Changes occurring in the hormone levels of normal women (left) and men (right) during the aging
process. Estrogen secretion throughout an individual normal woman’s life (expressed as urinary estro-
gen excretion) is shown at the top left [after (22)], and the mean free T index (the ratio of serum total T to
sex hormone–binding globulin levels) during the lifespan of healthy men is shown at the top right. In the
middle panels, serum DHEAS concentrations in 114 healthy women (left) and 163 healthy men (right) are
shown [adapted from (26)]. In the lower panel, the course of serum IGF-I concentrations in 131 healthy
women (left) and 223 healthy men (right) during aging is shown [adapted from (28)]. Note the difference
in the distribution of ages in the different panels.
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that tamoxifen has variable anti- and estro-
genic actions in different tissues (37). Ta-
moxifen suppresses the growth of estrogen
receptor–positive breast cancer cells. Long-
term treatment of menopausal breast cancer
patients with tamoxifen also lowered the
incidence of new (contralateral) breast can-
cers by 40%: In addition, the number of
cardiovascular incidents decreased by 70%,
and the age-related decrease in bone min-
eral density was partially prevented (38).
These initially puzzling observations were
explained by the fact that tamoxifen, and
other compounds such as raloxifene, have
estrogen receptor–modulating effects, ex-
erting anti-estrogenic actions on normal
and cancerous breast tissue but agonistic
actions on bone, lipids, and the blood vessel
walls (39). These effects of tamoxifen and
raloxifene may be explained by differential
stabilization of the conformations of the
estrogen receptor, but might also relate to
the activation of different estrogen receptor
forms, in which the a form is the “classical”
estrogen receptor, whereas a b form medi-
ates the vascular and bone effects of estro-
gens (40). It remains to be seen whether
compounds such as raloxifene have clinical-
ly important beneficial effects on bone
density, the vascular wall, and the brain, as
well as inhibition of the development of
breast cancer without inducing endometri-
um hyperplasia.
Age-associated changes in T levels occur
slowly and subtly (Fig. 3). More than 60%
of healthy elderly men over 65 years of age
have free T levels below the normal values
of men aged 30 to 35 (41). The variability
in circulating (free) T levels among elderly
men is considerable, however. Numerous
studies of large populations of healthy men
have shown a marked rise in the incidence
of impotence to over 50% in men aged 60
to 70 (42). Although this increase in impo-
tence seems to occur in the same age group
that shows a clear decline in free T levels,
no causal relationships have been demon-
strated. Testosterone replacement therapy
is in most instances not effective for the
treatment of impotence in elderly males;
other factors such as atherosclerosis, alcohol
consumption, smoking, and the quality of
personal relationships seem to be more im-
portant denominators (43).
Testosterone has long been known for
its anabolic effects (44). It is unknown,
however, whether the age-related decline
in muscle mass and muscle strength is
causatively related to the parallel decrease
in free T levels. Muscle weakness, anemia,
lowered bone mass, and mood disturbanc-
es rapidly normalize in mid-adult hypogo-
nadal men during T replacement therapy
(44). In addition, treatment of eugonadal
adult men with pharmacological doses of
T increases muscle mass and strength, es-
pecially in combination with exercise or
weight training (45). Very few long-term,
placebo-controlled studies on T replace-
ment in the frail elderly have been report-
ed. The data available point to a positive
effect on muscle mass and strength, as well
as on cognition and the sense of well-
being (46). An increase in hematocrit and
in the number of red blood cells, as well as
a slightly unfavorably effect on lipid pro-
files, have also been reported during T
treatment (46). T replacement therapy in
elderly men is limited in its use, however,
because of its unpredictable effects on the
size of the prostate. Although some studies
report no effects on circulating prostate-
specific antigen (PSA) levels, prostate
volume, or symptoms of urinary outlet ob-
struction, a modest irreversible increase in
PSA levels has also been observed during
T administration (46). No firm data are
available at present concerning a growth-
stimulatory effect of T on in situ prostatic
cancerous lesions, which frequently occur
in elderly men.
Few studies are available on the effects
of T replacement therapy in the elderly.
Dose, duration of treatment, the identifica-
tion of elderly men who might benefit most,
risks to the prostate, and possible effects on
the process of atherosclerosis remain sub-
jects for study. The concept of developing
androgenic compounds with variable bio-
logical actions in different organs (anti-
androgenic in the prostate) is currently be-
ing pursued, but the selection of aging men
with clinically important and well-defined
hypogonadism remains difficult, a situation
that contrasts sharply with abrupt meno-
pause in women.
Adrenopause
Circulating DHEAS levels in healthy
adults are more than 10 times higher than
those of cortisol (26). Animal studies in
rodents, which have very low circulating
DHEAS levels, suggest that DHEA ad-
ministration prevents obesity, diabetes
mellitus, cancer, and heart disease, while
enhancing immune function (27). These
results suggest that DHEA prolongs life-
span and might be an “elixir of youth.”
Supportive data in humans are few and
highly controversial. Higher DHEAS lev-
els are accompanied by a modestly reduced
risk of death from cardiovascular disease in
males (47). Functional parameters of ac-
tivities of daily living in males over 90
years old were lowest in those with the
lowest DHEAS levels (26). At age 30,
DHEAS levels are approximately five
times higher than at age 85 (Fig. 3) (26).
DHEA is a universal precursor for andro-
genic and estrogenic steroid formation in
peripheral tissues, which contain a num-
ber of DHEA-metabolizing enzymes (27).
Two randomized placebo-controlled
studies support the concept that oral ad-
ministration of DHEA has beneficial ef-
fects (48). Three months of daily treat-
ment with 50 mg of DHEA of 20 adults,
most of whom were nonelderly individuals
(40 to 70 years old), increased DHEA(S)
levels to young adult levels, increased
plasma androgen and IGF-I concentra-
tions, and induced a remarkable increase
in perceived physical and psychological
well-being in both sexes without an effect
on libido (48). In a subsequent study,
treatment with 100 mg of DHEA for 6
months in eight men and eight women
increased lean body mass in both sexes but
Table 1. Lifetime probabilities of disease occurrence for a 50-year-old white woman treated with
long-term hormone replacement [from a meta-analysis by Grady et al. (32)]. E2 1 P 5 estrogen plus
progestin. The estimated lifetime probabilities of developing the conditions mentioned have been
derived from mortality and incidence data from the 1987 Vital Statistics of the United States and other
sources mentioned in appendix 2 of (32). The relative risks are the “best” estimates of the relative risk for
developing each condition in long-term hormone users as compared with nonusers. These estimates
were derived from a model of the risks and benefits of hormone therapy developed by Grady et al. (32).
A number of limitations and assumptions have to be taken into consideration when interpreting this
table: The duration of the use and dose regimens of E2 1 P varied considerably between studies
included in the meta-analysis (duration ranged from 2 to 10 years). It was assumed that the addition of
progestin to the estrogen regimen would increase the risk of breast cancer from 1.25 to 2.0.
Condition
Lifetime probability (%)
Relative risk
No treatment E2 1 P
Coronary heart disease 46.1 13.7**–34.4 0.04**–0.65
Stroke 19.8 19.3 0.96
Hip fracture 15.3 12.0 0.75
Alzheimer’s disease* 16.3 5.8 0.40
Breast cancer 10.2 13.0–19.7 1.25–2.00
Endometrial cancer 2.6 2.6 1.00
Life expectancy (years) 82.8 83.8
*Adapted according to Tang (34). **Adapted according to Grodstein (65).
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increased muscle strength in the men only
(38).
It is unknown whether the increase in
sex steroid levels induced by DHEA is safe
with regard to the development of ovarian,
prostate, or other types of cancer. DHEA is
currently widely used in the United States
as a “treatment for aging.” With the scien-
tific verdict still out, without confirmation
of DHEA’s reported beneficial actions in
humans, and without a better understand-
ing of its potential risks, it is premature to
recommend the routine use of DHEA for
delaying or preventing the physiologic con-
sequences of aging (49).
Somatopause
Little is known concerning the biological
consequences of somatopause (50). In sev-
eral studies of healthy individuals of a
broad age range, an association was ob-
served between the maximum aerobic ca-
pacity and circulating IGF-I levels (51).
The expectation that somatopause con-
tributes to the decline of functional capac-
ity in the elderly is mainly derived from
studies in which GH replacement therapy
of GH-deficient adults was shown to in-
crease muscle mass, muscle strength, bone
mass, and the quality of life. A beneficial
effect on the lipid profile and an impor-
tant decrease in fat mass were also ob-
served in such patients (52). As in hy-
pogonadal individuals, adult GH deficien-
cy is considered a model of normal aging,
because a number of catabolic processes
that are central in the biology of aging can
be reversed by GH administration.
GH administration for 3 to 6 months to
healthy elderly individuals increased IGF-I
levels to those observed in control individ-
uals half their age, while muscle mass, skin
thickness, and bone mineral content signif-
icantly increased and fat mass decreased
(53). A disappointing aspect of the studies
is that no positive effect of GH therapy was
observed on muscle strength and maximal
oxygen consumption (54). If GH was ad-
ministered in combination with resistance
exercise training, however, a significant
positive effect on muscle mass and muscle
strength was recorded that did not differ
from that seen with placebo treatment,
which suggests that GH does not add to the
beneficial effects of exercise (55).
Earlier studies have demonstrated that
pharmacological doses of GH prevent the
“auto-cannibalistic” effects of acute diseases
on muscle mass (56). This prompted us to
carry out a randomized placebo-controlled
trial of 6 weeks of GH administration in
elderly individuals with an acute hip frac-
ture. Our preliminary results indicate that
in individuals over 75 years old, GH admin-
istration causes a statistically significant
earlier return to independent living after
the fracture. Comparable studies are cur-
rently being done in several countries, and
confirmation is needed before GH might
gain a place in the treatment of acute cat-
abolic states in the frail elderly.
Other components in the regulation of
the GH/IGF-I axis are effective in activat-
ing GH and IGF-I secretion. Long-acting
derivatives of the hypothalamic peptide
growth hormone releasing hormone
(GHRH), given twice daily subcutaneously
for 14 days to healthy men 70 years old,
increased GH and IGF-I levels to those
encountered in 35-year-olds (57). These
studies support the concept that somato-
pause is primarily hypothalamically driven
and that pituitary somatotrops retain their
capacity to synthesize and secrete high lev-
els of GH. GH releasing peptides (GHRPs)
are oligopeptides with even more powerful
GH-releasing effects (58). Originally devel-
oped by design, it has recently been suggest-
ed that they mediate their GH-secretory
effects through endogenous specific recep-
tors (59). Nonpeptide analogs such as MK-
677 and L-692,429 have powerful GH-re-
leasing effects, restoring IGF-I secretion in
the elderly to levels encountered in young
adults (60). Long-term oral administration
of MK-677 to healthy elderly individuals
increased lean body mass but not muscle
strength. If proven to be GH-specific, these
orally active GHRP derivatives might be
important alternatives to subcutaneously
administered GH in the reversal of somato-
pause, in the prevention of frailty, and in
the reversal of acute catabolism. The long-
term safety of the activation of GH/IGF-I
levels remains uncertain with regard to tu-
mor growth, as most human solid cancers
express IGF-I receptors (60).
The Concept of Successful Aging
There is considerable variation in the ef-
fects of aging on healthy individuals, with
some persons exhibiting extensive alter-
ation in physiological functions with age
and others little or none. It has been
suggested that it might be useful to distin-
guish between usual and successful pat-
terns of aging (61). Genetic factors, life-
style, and societal investments in a safe
and healthful environment are important
aspects of successful aging (62). Tradition-
ally, the aging process, including the de-
velopment of physical frailty toward the
end of life, has been considered to be
physiological and unavoidable. In recent
years, however, it has become evident that
it might not be necessary to accept the
grim stereotype of aging as an unalterable
process of decline and loss (9, 61). As life
expectancy increases further in coming
decades, the overarching goal for the year
2000 and thereafter should be “an increase
in years of healthy life with a full range of
functional capacity at each stage of life”
(63). Such a compression of morbidity can
often be achieved through lifestyle mea-
sures, but a number of aspects of the aging
process of the endocrine system invite the
development of “routine” medical inter-
vention programs offering long-term re-
placement therapy with one or more hor-
mones, in order to delay the aging process
and to allow us to live for a longer period
in a relatively intact state.
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